Actively Recruiting
Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia
Led by Peking Union Medical College Hospital · Updated on 2025-01-01
120
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with hyperlipidemia will be allocated into intervention or control group randomly. Participants of intervention group will be provided with Omega-3 PUFA, while participants of control group will be provided with placebo which looked same as the drug of intervention group. During the study, all participants can have nutritional counseling and education for low-fat diet. The lipids, inflammatory factors, weight, and body composition will be assessed and recorded before, at the middle, and end of the study.
CONDITIONS
Official Title
Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years old and above
- Diagnosed with hyperlipidemia meeting clinical criteria: triglycerides ≥1.7 mmol/L, or total cholesterol ≥5.2 mmol/L, or LDL cholesterol ≥3.4 mmol/L
- Fully understand and voluntarily sign informed consent
- Able to eat orally
- Able to follow the research protocol and comply with doctor and researcher instructions
You will not qualify if you...
- Currently receiving lipid-lowering drugs
- Hyperlipidemia caused by secondary conditions such as nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, glycogen storage disease, myeloma, fat atrophy, acute porphyria, polycystic ovary syndrome, or use of certain medications causing secondary dyslipidemia
- Severe diseases including heart, liver, kidney dysfunction, recent acute myocardial infarction, stroke, intracerebral hemorrhage, acute COPD attack, respiratory failure within 3 months; recent surgery within 3 months; or deemed unsuitable by clinician
- Hemorrhagic disease or bleeding tendency
- History of allergy to omega-3 polyenoic acid preparations
- Pregnant or lactating women
- Poor compliance or inability to complete follow-up
- Serious abnormal metabolism or need for further intervention making continued participation unsuitable as assessed by physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospita
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
K
Kang Yu, master
CONTACT
F
Fang Wang, master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here